France’s healthcare system is to benefit from €7bn worth of investment, which is designed to drive innovation in the sector. Speaking at the end of June, French President Emmanuel Macron announced that public funding would be made available in the wake of the COVID-19 pandemic in the country. Part of France’s Health Innovation Plan 2030, €2bn will be invested by the state-owned Banque Publique d'Investissement (BPI) in start-ups and small and medium-sized companies (SMEs) in the healthcare industry. France will also invest €2bn in research for emerging and infectious diseases, biotherapies and digital health. Following the COVID-19 pandemic, the plan will allocate almost €750 million for emerging infectious diseases and CBRN (nuclear, radiological, biological and chemical) threats. Another €800m will be dedicated to biotherapies and the bioproduction of innovative therapies that represent 50% of the clinical trials currently underway. These technologies enable the development of so-called personalised medicine by providing therapeutic solutions in oncology, immunology, virology and for rare diseases, for example. President Macron wants to make France the leading European country in healthcare innovation by 2030. He has committed to lift administrative hurdles to speed up organisational changes in the healthcare system. *Image by Parentingupstream from Pixabay
Newsweek, in collaboration with Statista Inc., has compiled a league table of the world’s best specialized hospitals 2021, and France has no less than 26 Cancer Centers (CLCCs) in the top 200. Topping the list of French oncology hospitals is Institut Gustave Roussy in Villejuif, which ranked fifth in the overall oncology list. Two more French cancer centers – Institut Curie and Hôpital Universitaire Pitié Salpêtrière – were also in the top 50, ranking 12th and 31st respectively. All in all, 26 French cancer hospitals were included in the top 200 global oncology list, highlighting just how renowned these establishments are on the international medical stage. Speaking about the rankings, Jean-Yves Blay, President of Unicancer – the National Federation of French Cancer Centres – said: “We are proud to see that more than half of CLCCs are ranked among the best cancer hospitals in the world. The model of care for cancer patients within the CLCCs is unique and this international recognition underscores the strength and excellence of our network, supported by common values and commitments, at the service of the patient. It also testifies to our constant quest for excellence in healthcare, research and higher education.” For the rankings, Newsweek and Statista surveyed more than 40,000 medical experts from over 20 countries. A global board of experts was then asked to review and rank the hospitals outlined in the survey. You can check out the full Newsweek oncology ranking here.
If there wasn’t already enough motivation for overweight men to shed some pounds, new research suggests losing weight could help lower the risk of advanced prostate cancer. Prostate cancer is the second most common cancer in men globally, with approximately 1.3 million new cases in 2018 alone. Fortunately, if discovered early enough, prostate cancer has a relatively low mortality rate, with 96% of patients surviving for 15 years or more following an early stage diagnosis. However, as with any cancer, prevention is better than cure, and survival rates for advanced prostate cancer are very poor. That’s why a new, large-scale analysis of 15 studies involving nearly 831,000 men is significant. It found that having a Body Mass Index (BMI) of above 25 during middle to late adulthood was associated with the highest risk for advanced prostate cancer. Furthermore, the researchers from the Mailman School of Public Health at Columbia University found that having a larger waist size was also associated with an increased risk of advanced prostate cancer and death. “These study results show that risk for advanced prostate cancer can be decreased by maintaining a 'healthy' weight, which is in line with guidelines by the American Cancer Society and World Cancer Research Fund,” said study author Jeanine Genkinger, an associate professor of epidemiology at the Mailman School of Public Health The study was published March 4 in the Annals of Oncology.
Prostate cancer is the most common cancer in men in the UK, with more than 47,000 new cases diagnosed every year. And up until now, the most widely used tests for the disease had included the PSA blood test, a digital rectal examination (DRE), MRI scans and a biopsy. However, each of these wasn’t without its problems. But now a new ultrasound process, which offers more successful diagnosis and management of prostate cancer, has been identified by researchers at Dundee University. The technique, known as non-invasive shear wave elastography (SWE), offers "much greater accuracy and reliability" than current methods and is less expensive, according to the researchers. It targets the prostate with ultrasound and was evaluated using a study at Dundee University involving around 200 patients. Because cancerous tissue is denser than normal tissue, the shear waves are slowed as they pass through it. During the study, the technique was able to successfully identify 89% of prostate cancers, as well as other more aggressive cancers, including those spreading outside of the prostate. Ghulam Nabi, professor of surgical uro-oncology at Dundee University, said, "Prostate cancer is one of the most difficult to pinpoint. "We are still in a position where our diagnosis of prostate cancer is extremely inefficient, leading to unnecessary treatments for many patients." Speaking about the new test, Prof Nabi said it was “like someone has turned the lights on in a darkened room."
New figures show that for the first time ever the number of men dying from prostate cancer in the UK has overtaken female deaths from breast cancer. While lung and bowel cancer remain the top cancer killers, prostate cancer is now third, according to figures released by Prostate Cancer UK. In 2015, 11,819 men died from prostate cancer, compared to 11,442 women from breast cancer – a reality that Prostate Cancer UK says is due to advances in diagnosis and treatment of breast cancer. The charity says that the UK’s aging population is one of the reasons why more men are developing and dying from prostate cancer. Angela Culhane, chief executive of Prostate Cancer UK, said prostate cancer survival rates could be increased by developing better diagnostic tests and using them to form a nationwide screening programme. At present, there is no single, reliable test for prostate cancer. Also, men with the disease can live for decades without showing any symptoms. Those most at risk are men with male relatives who have had the disease, black men and men aged over 50. Ms Culhane said: “It's incredibly encouraging to see the tremendous progress that has been made in breast cancer over recent years. “The good news is that many of these developments could be applied to prostate cancer and we're confident that with the right funding, we can dramatically reduce deaths within the next decade.” You can find out more about prostate cancer treatment with us here at France Surgery by visiting the oncology section of our website and selecting the prostate cancer link.
A simple blood test that accurately detects several different types of cancer years before symptoms even appear could revolutionise how the disease is treated, scientists have said. Researchers hope the non-invasive test will pave the way for a future where the straightforward procedure could form part of routine health check-ups. It’s thought that thousands of deaths each year could be prevented with the tests as they can detect tumours at an early stage, when treatment is most effective. At present, the best method for detecting cancer is a biopsy, which involves cutting out a small piece of tumour tissue for lab analysis. However, biopsies are invasive and often painful, and a person already needs to have a tumour or at least a suspected tumour to have something cut out of it. That’s why scientists have been working to develop blood tests that can do the same, without the need for surgery. Speaking about the breakthrough, Dr Bert Vogelstein, a professor of oncology at Johns Hopkins School of Medicine, told The Guardian: “It’s fair to say that if you could detect all cancers while they are still localized, you could diminish cancer deaths by 90 per cent.”
A new treatment for early stage prostate cancer has been described as "truly transformative" by surgeons. The approach, which has been tested across Europe, uses lasers and a drug made from deep sea bacteria to eliminate tumours, without any severe side effects. The results of clinical trials on some 413 men, which were published in The Lancet Oncology, showed nearly half of them had no remaining trace of cancer. One of the biggest issues for men with early stage prostate cancer is that treatment often leads to lifelong impotence and incontinence. That's why many men choose the "wait and see" approach when they are diagnosed in the early stages and only opt for treatment if their cancer starts growing aggressively. These new findings turn that approach on its head and "change everything," according to Prof Mark Emberton, who tested the technique at University College London. The bacteria that the drug is made from live in total darkness and become toxic when exposed to light. This is how the new treatment works. Fibre optic lasers are inserted through the perineum (the gap between the anus and the testes) and into the cancerous prostate gland. When they are activated the drug kills the cancer and leaves the healthy prostate behind. While the fact that 49% of patients went into complete remission is remarkable in itself, the additional finding that impact on sexual activity and urination lasted for no more than three months makes the treatment even more amazing. Even though more research is needed, the findings of the study are being hailed as "truly transformative" for prostate cancer patients.
It's been thought for some time now that a mother's weight and diet during pregnancy has the potential to affect the breast cancer risk of her female offspring. But now new research suggests that obese father's also risk raising their children's chances of breast cancer, due to the way obesity alters the gene expression of sperm. Experts have long agreed that a woman's breast cancer risk is influenced by changes in genes, and approximately 5-10 percent of these gene changes are inherited. According to Sonia de Assis, Ph.D., from the Department of Oncology at Georgetown Lombardi Comprehensive Cancer Centre in Washington, D.C., who led the investigative team, said few studies have previously investigated the link between a father's weight and an offspring's breast cancer risk in later life. Presenting their findings in the journal Scientific Reports, de Assis and her colleagues outlined how they had studied how both normal weight male mice and obese male mice influence the breast tissue off their offspring. They found that female pups sired by obese males had delayed breast tissue development, and were more likely to develop breast cancer as a result. They revealed that the obese males' sperm had an altered microRNA (miRNA) signature, which was subsequently found in the breast tissue of their female offspring. The researchers now plan to conduct more studies to see if the same is true in humans.
Our immune systems are able to fight bacteria, viruses and microbes. Therefore, you'd like to think that they could play a vital role in the fight against cancer too. Over the past 30 years, immunotherapy has emerged and grown as a therapeutic strategy in the field of oncology. This new class of cancer treatment harnesses the power of the immune system and its unique properties to fight cancer in a way that is more powerful than many that have come before it. Immunotherapy is also an exciting weapon for fighting cancer because of the potential long-term protection it gives against the disease; the fact that it causes fewer side effects than other traditional therapies; and can benefit more patients with different types of cancer. With this in mind, a team in Toulouse is looking to build upon the already fantastic base that immunotherapy has to make it an even more potent cancer therapy. They are looking to discover which patients respond to the treatment best, and Dr. Michel Attal, managing director of the Cancer Research Centre of Toulouse, said: "This is just the beginning. In the coming years, all cancer patients will, at one time or another, be treated with immunotherapy."
This month, the capital of France’s southern Midi-Pyrénées region, Toulouse, will host the Toulouse Onco Week (TOW) – a three day event dedicated to the fight against cancer. Toulouse Onco Week will be held on the 3rd, 4th and 5th February under the high patronage of the President of France, Mr. François Hollande. One of TOW’s biggest highlights will be the inauguration of the first international meeting of the Cancer Research Centre of Toulouse. This focal point will see sixteen international oncology experts (researchers and clinicians) come together with two Nobel Prize winning professors - Pr. Jules Hoffmann and Pr. Gerd Binnig – to advance oncology research and therapeutic care development. A series of one-to-one meetings, technology presentations, public sessions and charity events will round off what is going to be one of the most important occasions in the oncology calendar this year. More information about Toulouse Onco Week can be found on the official website. France Surgery will be supporting the event and we hope you will be too…
Here at France Surgery, we’re all about promoting health and wellbeing. Eating right, exercising regularly and maintaining a healthy mind, by practising yoga or meditating, for example, are all things we encourage our patients and worldwide followers to do. But now a new study has found that yoga, in particular, could benefit male prostate cancer patients who are undergoing radiation therapy. More often than not, male prostate cancer patients experience a range of side effects while receiving radiation therapy, including fatigue, urinary incontinence, erectile dysfunction and a general decline in their overall quality of life. The new study, however, despite being small, showed found that men who attended a 75-minute yoga class twice a week experienced a stable quality of life throughout. Furthermore, their side effects also remained stable over the same period. In a press release, Dr. Neha Vapiwala, an associate professor in the radiation oncology department of the Perelman School of Medicine at the University of Pennsylvania, said: "Data have consistently shown declines in these important measures among prostate cancer patients undergoing cancer therapy without any structured fitness interventions, so the stable scores seen with our yoga program are really good news." The researchers suggest that regular yoga strengthens pelvic floor muscles and increases blood flow, which could have a positive impact on erectile dysfunction and urinary incontinence. Moreover, the satisfaction and general happiness that patients get from participating in a group fitness activity further boost their quality of life. With nearly 240,000 American men each year diagnosed with prostate cancer, according to the American Cancer Society, which funded the study, research such as this has the ability to vastly improve the quality of life of male prostate cancer patients going forward.
People have talked about the possible negative effects of processed meat for a long time and numerous studies linking high consumption of red and processed meats with higher risk of colorectal cancer have even influenced public health recommendations in some countries. But now a report compiled on behalf of the World Health Organisation by a working group of 22 experts from 10 countries around the world has concluded that there is an association with eating processed meats and colorectal cancer risks. The findings, published recently in The Lancet Oncology, said that 50g of processed meat a day, which is equivalent to less than two slices of bacon, increased a person’s chances of developing colorectal cancer by 18%. Furthermore, the study said that red meats were “probably carcinogenic, but there was limited evidence to comment further. However, despite these findings, the WHO also emphasised that there are still health benefits associated with eating meat. Cancer Research UK’s advice is that people should cut down on their consumption of red and processed meats, rather than give them up completely. In fact, the organisation said that the occasional bacon sandwich would do little harm. Processed meat is meat that has had its shelf life extended or its taste changed by means of smoking, curing, or adding preservatives or salt. Bacon, sausages, hotdogs, corned beef, salami, ham, beef jerky and other canned meats are all considered “processed”. Chemicals used during the processing of the meats are thought to be carcinogenic catalysts, as is high-temperature cooking such as on a barbecue. Dr Kurt Straif from the WHO said: “For an individual, the risk of developing colorectal (bowel) cancer because of their consumption of processed meat remains small, but this risk increases with the amount of meat consumed.”
A study of 582 people, conducted in Europe and the US, has found that Nivolumab leaves cancer cells open to attack from the body’s immune system by preventing them from being able to hide. Lung cancer kills almost 1.6 million people worldwide every year and is particularly difficult to treat as it is usually diagnosed late and sufferers often have other smoking-related diseases which make them unsuitable for surgery. The trial involved patients who had advanced lung cancer and had already tried other treatments. Individuals who were on standard therapy at this stage lived for another 9.4 months, but those being treated with Nivolumab lived for an average of 12.2 months. However, patients whose tumours were producing high levels of PD-L1 – a protein that inhibits the body’s natural defences – lived for another 19.4 months after taking Nivolumab. The study’s lead researcher, Dr Luis Paz-Ares from the Hospital Universitario Doce de Octubre in Madrid, Spain, said: "[The results] mark a milestone in the development of new treatment options for lung cancer." The data was presented by pharmaceutical company Bristol-Myers Squibb to the American Society of Clinical Oncology and the findings were described as "giving real hope to patients". Cancer Research UK welcomed the results of the study and said that harnessing the power of the body’s immune system would be an "essential part" of cancer treatment. Photo credit: Phys.org
For prostate cancer sufferers, docetaxel is usually only given after hormone treatment has failed. But now a major study has revealed that earlier treatment with the drug can extend life expectancy anywhere from 43 to 65 months. The results, which will be presented at the American Society of Clinical Oncology, are being labelled as “potentially game-changing”. In the UK alone, 40,000 men are diagnosed with prostate cancer and 11,000 die from the disease every year. The trial was conducted across Britain and Switzerland and involved 2,962 men. At the start of their treatment, some of the men were given six doses of docetaxel and subsequently lived 10 months longer than those that weren’t. However, patients who had already seen their cancer spread past their pelvis saw their life expectancies increase by 22 months. One of the researchers at Warwick University, Prof Nicholas James, who was involved in the study said he was very pleased with the results and emphasised that the NHS needed to act upon them quickly: "To see a 22-month survival advantage off six lots of treatment given several years earlier is a very big benefit.” Furthermore, the fact that docetaxel is out of patent means that it represents a potentially cost-effective method of treatment. Commenting on the study’s findings, Cancer Research UK said the results were “important” and "show that it should be given earlier in a man's treatment". Photo credit: NHS
Clinique Saint-Jean de Dieu, Paris It is animated by the same spirit of innovation and humanity as St. Jean de Dieu, creator of the modern hospital, recognized precursor for hygiene and modern care. Magallon brother Paul founded the clinic in 1843. Today the clinic is a category A listed clinic, with: - 83 hospital beds across four medical ward - 7 posts outpatient chemotherapy, and medical oncology consultation - 7 operating rooms - 12 posts post-interventional monitoring - 1 central sterilization unit - consultation services - 1 Department of Radiology - mammography referenced for breast cancer' screening in Île-de-France And medical professionals committed to the daily well-being of patients.
The American Hospital of Paris, Paris Created one hundred years ago thanks to the energy and generosity of the men and women of the American community in Paris, the American Hospital of Paris has continued its tireless development thanks to the support of its donors. Located on the western border of Paris, the American Hospital of Paris is a ten-minute drive from Place Charles de Gaulle-Étoile. Key figures In-patient hospital beds 141 Intensive care units 8 Coronary care units 6 Day hospital beds 20 Nursing staff 345 Medical technicians 225 Accredited physicians and surgeons 386 The American Hospital of Paris offers personalized patient services, safety, quality of care, and respect for all cultures. It covers all major medical and surgical specializations and it offers comprehensive diagnostics and testing, from lab exams to the most advanced imaging procedures (such as MRI, CT and PET scans). The hospital disposes of the latest-generation equipment and innovative techniques (robotic surgery, CZT gamma camera) and proposes premium patient accommodations, such as private suites and rooms with terrace, room service, etc. The English-speaking healthcare staff has a substantial experience in delivering care to international patients: patients of over 100 different nationalities are treated each year. The physicians of the American Hospital of Paris include around 400 private, bilingual practioners, covering the entire spectrum of major medical and surgical specialties. A team of private healthcare professionals works alongside them in patient care. List of departments and units Aesthetic and Plastic Surgery Anaesthesiology Cardiology Dentistry / Stomatology Emergency ENT Gastroenterology General and Digestive Surgery Gynaecology Medical Imaging and Nuclear Medicine Medicine Nephrology Neurology Oncology Ophthalmology Orthopaedics Pediatrics Pediatric Surgery Pneumology Prenatal Diagnosis Psychiatry Rheumatology Urology Vascular The Emergency Department of the American Hospital of Paris operates 24/7, providing care to adults in a medical or surgical emergency. The Check-up Centre has been exclusively dedicated to providing patients with preventive care and screening using the most advanced technologies and up-to-date scientific recommendations. International services: The American Hospital of Paris has several programs dedicated to serving our international patients: the American Relations Coordinator, the International Team, the Japanese Program and the Chinese Program.
Clinique du Pont de Chaume, Montauban The Clinique du Pont de Chaume is a private institution with a capacity of 280 beds of which 45 orthopaedic beds, and has enjoyed a continuous growth in the last 10 years. The Hospital has been expanded in 2001 with a new operating theatre, digitalised equipment and CAO technology. The hospital has the following specialities : general, vascular, urologic surgery, oncology, medicine, emergency, intensive care unit, radiology (MRI, TDM) scintigraphy. The orthopaedic surgeons team consists of five surgeons with different specialities. Over 500 joint reconstructions are performed per year. Quality and safety of care: Clinique du Pont de Chaume was fully accredited by the highest French Health Authority (HAS) since 2005. It was ranked 17th best clinic out of 1 600 French establishments in 2011 for orthopaedics, national study performed by “Le guide Santé” magazine. THE CLINIC 25,000 m2 of buildings 180 hospital rooms One of the largest hemodialysis centre in South West France 1 intensive care unit 1 unit for post surgical monitoring 13 operating rooms 1 endoscopy unit 10 rooms, radiology, echography and CT 1 radiotherapy centre 1 nuclear medicine centre 1 medical biology laboratory 1 emergency service open 24/24 AND ALSO… 100 specialists, 450 employees, 150 professional staff in medical offices for a total of 700 people at your service to accommodate each year more than 15,000 inpatients, 15,000 emergency and 180,000 outpatients received in 22 medical practices.
Located in the beautiful Midi-Pyrénées region of Southern France, our Pont de Chaume clinic in Montauban has been fully accredited by the French Health Authority (HAS) since 2005. So it almost goes without saying that you will receive the highest level of care and service when staying for your treatment or procedure. We’re a privately run health facility that has enjoyed continuous growth over the last 10 years. Due to this success the clinic has expanded over the years to accommodate and better service the many patients who arrive each year. Amongst these expansions has been the installation of new a state-of-the-art operating theatre, digitalised equipment and CAO technology. Whilst we provide a full range of medical and surgical procedures, our specialist areas are vascular, urologic surgery, oncology and radiology (MRI, TDM). Our orthopaedic team consists of five top surgeons each with their own specialism, so you can be assured of being treated by a surgeon matching your individual needs. And of course, we also have an emergency services department operating 24/7 as well as an intensive care unit. Whatever your needs, let our team of internationally renowned healthcare professionals be on hand to make your stay with us, the best it can possibly be. Get in touch with us today for further information or to discuss your requirements in more detail. Photo credits: Clinique du Pont de Chaume
ONCOLOGY AND HAEMATOLOGY PERSONALISED CARE ADHERING TO THE LATEST CANCER TREATMENTS PROTOCOLS The medical team that supports you is made up of internationally renowned healthcare professionals from different areas of specialty. They work within the health care facility where you receive your treatment and in connection with your doctors. Your support is comprehensive and includes care and additional support you may need during and after your treatment (psychological, fatigue management, advice on your diet ...). Cancer Screening and Early Detection Screening is a process that aims to identify, at the earliest and in the absence of symptoms, lesions that may be cancerous or develop into cancer. The value of screening is that cancer can be detected earlier, patients can be provided with better care and the impact of treatment is reduced. For all requests, you must first send us a completed medical record via our secure platform as well as your medical history. This will allow us to put you in touch with the best French specialists who can discuss the treatments options suitable for you. Incomplete or unreadable medical documents will not be accepted. Choose an institution To be allowed to treat cancer, French healthcare institutions have to meet a number of conditions that are a guarantee that you to be well supported. You are free to choose the institution where you want to be treated.